CorMedix Inc. (CRMD) financial statements (2020 and earlier)

Company profile

Business Address 400 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments281812203542
Cash and cash equivalents16181081242
Short-term investments12 21224  
Receivables 000000
Inventory, net of allowances, customer advances and progress billings0010000
Inventory0010000
Prepaid expense00010 0
Deferred costs      0
Other undisclosed current assets1111100
Total current assets:291913223753
Noncurrent Assets
Property, plant and equipment0000000
Deposits noncurrent assets   0000
Other undisclosed noncurrent assets      0
Total noncurrent assets:0000000
TOTAL ASSETS:291913223753
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6864312
Accounts payable1322211
Accrued liabilities5542111
Employee-related liabilities     00
Deferred revenue0
Other undisclosed current liabilities 0000(0)(0)
Total current liabilities:6864312
Noncurrent Liabilities
Long-term debt and lease obligation06     
Long-term debt, excluding current maturities 6     
Operating lease, liability0
Liabilities, other than long-term debt    005
Deferred revenue and credits  000
Derivative instruments and hedges, liabilities      5
Total noncurrent liabilities:06  005
Total liabilities:61464317
Stockholders' equity
Stockholders' equity attributable to parent, including:245718344(4)
Preferred stock0000000
Common stock0000000
Common stock, value, subscriptions15     
Additional paid in capital01841591371288052
Deferred compensation equity    (0)(0)(0)
Accumulated other comprehensive income (loss)000000(0)
Accumulated deficit(195)(179)(152)(119)(94)  
Warrants and rights outstanding     12 
Other undisclosed stockholders' equity attributable to parent204    (88)(56)
Total stockholders' equity:245718344(4)
TOTAL LIABILITIES AND EQUITY:291913223753

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues0000000
Cost of revenue(0)(0)(0)    
Other undisclosed gross profit   (0)(0)(0)(0)
Gross profit:(0)00(0)(0)(0)(0)
Operating expenses(21)(27)(33)(25)(17)(9)(5)
Other operating expense, net
(Other Expenses)
(0)      
Other undisclosed operating income0      
Operating loss:(21)(27)(33)(25)(17)(9)(5)
Nonoperating income (expense)00000(0)(0)
Investment income, nonoperating0 00000
Foreign currency transaction loss, before tax(0) (0)(0)(0)(0) 
Other nonoperating income (expense) 0    (0)
Interest and debt expense(1)(0)(0)(0)(0)(0)(3)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)0(0)(0)(2)(11)(1)
Loss from continuing operations before equity method investments, income taxes:(21)(27)(33)(25)(18)(20)(9)
Other undisclosed income from continuing operations before income taxes0      
Loss from continuing operations before income taxes:(21)(27)(33)(25)(18)(20)(9)
Income tax benefit5      
Net loss:(16)(27)(33)(25)(18)(20)(9)
Other undisclosed net income attributable to parent  0    
Net loss attributable to parent:(16)(27)(33)(25)(18)(20)(9)
Preferred stock dividends and other adjustments    000
Other undisclosed net loss available to common stockholders, basic(27)   (0)(0)(1)
Net loss available to common stockholders, diluted:(44)(27)(33)(25)(18)(21)(10)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(16)(27)(33)(25)(18)(20)(9)
Other comprehensive income (loss)0(0) 0(0)0 
Comprehensive loss:(16)(27)(33)(25)(18)(20)(9)
Other undisclosed comprehensive income, net of tax, attributable to parent  0    
Comprehensive loss, net of tax, attributable to parent:(16)(27)(33)(25)(18)(20)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: